Fennec Pharmaceuticals is trading 10.69% up at $12.11 after reporting strong second-quarter 2026 results before the August 11, 2026 market open.

  • Net product sales reached $17.1 million, up 78% year over year.
  • Adjusted EBITDA improved to $2.8 million from a $1.2 million loss.
  • Record PEDMARK demand and continued commercial expansion supported the upbeat business update.